Mind Medicine (MindMed) Inc. (MNMD)

9.55 +0.33 (+3.58%) 收市：04:00PM EDT

Mind Medicine (MindMed) Inc.

One World Trade Center
Suite 8500
New York, NY 10007
United States
212-220-6633
https://www.mindmed.co

版塊: Healthcare
行業: Biotechnology
全職員工: 57

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Robert Barrow	CEO & Director	931.13k	無	1989
Mr. Schond L. Greenway M.B.A.	Chief Financial Officer	608.62k	無	1972
Dr. Daniel Rollings Karlin M.A., M.D.	Chief Medical Officer	658.52k	無	1980
Dr. Miriam Halperin Wernli M.B.A., Ph.D.	Executive President	552.46k	無	1953
Dr. Scott M. Freeman M.D.	Co-Founder & Clinical Advisor	314.04k	無	1957
Mr. Leonard Latchman	Co-founder	無	無	無
Mr. Mark R. Sullivan J.D.	Chief Legal Officer & Corporate Secretary	無	無	1971
Dr. Francois P. Lilienthal M.B.A., M.D.	Chief Commercial Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

公司管治

截至 2024年5月1日 止，Mind Medicine (MindMed) Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：8；董事會：5；股東權利：3；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。